The FDA recently cleared a pharmacogenetic DNA test from 23andMe that is designed to determine how users will react to certain pharmaceutical drugs.
The FDA cleared the new 23andMe test to give information on 33 genetic variants that determine how patients will respond to more than 50 different prescribed and over-the-counter medications. The test, which involves spitting into a tube and sending it back to the company, will look at how patients will be able to metabolize certain medications.
Get the full story on our sister site, Drug Delivery Business.
The post FDA clears 23andMe for pharmacogenetics testing appeared first on MassDevice.